Everything below concerns LC-MS/MS. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-04-12. Where a claim depends on a specific study, the study is described rather than over-claimed.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
| Property | Value | Notes |
|---|---|---|
| Common synonym | hGH fragment 176-191 | Refers to the C-terminal segment |
| Appearance | White to off-white powder | Typically supplied lyophilized |
| Solubility | Soluble in water and aqueous buffers | Confirm with technical data |
| Typical storage temperature | -20 °C for dry powder | Protect from moisture and light |
| Common analytical method | RP-HPLC with UV detection | Often paired with mass spectrometry |
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
In optical interferometry, the pathlength difference between sample and reference arms can be measured by ToF methods, such as frequency modulation followed by phase shift measurement or cross correlation of signals. Such methods are used in laser radar and laser tracker systems for medium-long range distance measurement. In neutron time-of-flight scattering, a pulsed monochromatic neutron beam is scattered by a sample. The energy spectrum of the scattered neutrons is measured via time of flight. In kinematics, ToF is the duration in which a projectile is traveling through the air. Given the initial velocity
He was accused of rudeness and incompetence, and John Lewis Gaddis argues that he was also blamed with ruining Soviet agriculture, bringing the world to the brink of nuclear war, and becoming an "international embarrassment" when he authorized construction of the Berlin Wall. According to Dobrynin, the top Soviet leadership took the Cuban outcome as "a blow to its prestige bordering on humiliation".
While some strategies endorsed in the program, including needle-exchange programs and good samaritan laws, became mainstream in American drug policy, other approaches that were advocated at the conference, including safe injection sites, have yet to be widely endorsed in the United States. Nadelmann said at the time of the conference, "We could cut heroin overdoses in half if the information from this conference was widely disseminated."
Charles River Laboratories International, Incorporated is an American life sciences company and contract research organisation (CRO) headquartered in Wilmington, Massachusetts, United States. Founded in 1947, the company provides goods and services that support the development of drugs, vaccines, and other therapeutics. Its operations span at least 20 countries, offering research models, drug discovery and safety assessment, and manufacturing and testing services to pharmaceutical, biotechnology, government, and other clients. Charles River Laboratories is a global provider of non-clinical drug development services, known for its role in toxicology studies, research animal models, and microbial testing services used in regulatory submissions to health authorities such as the U.S. Food and Drug Administration (FDA). The company has also been the subject of public scrutiny and regulatory attention over its use of research animals, including dogs, primates, and horseshoe crabs. As of 2024, the company employs over 20,000 people worldwide and is publicly traded on the New York Stock Exchange under the ticker symbol CRL.
== Contraindications == Oliceridine should not be given to people with significant respiratory depression; acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment; known or suspected gastrointestinal obstruction; or known hypersensitivity to the medication.
Sources: en.wikipedia.org
Donepezil: Donepezil is a widely used acetylcholinesterase inhibitor indicated for Alzheimer's disease. The drug can be administered orally or with a transdermal patch. However, the estimated time to peak will differ between both routes of administration. Oral donepezil has a peak concentration time of 3 to 8 hours depending on the dosage, while transdermal donepezil has an expected time to peak at 7 days.
== Background of other taste categories == The five basic tastes (saltiness, sweetness, bitterness, sourness, and savoriness) are detected by specialized taste receptors on the tongue and palate epithelium. The number of taste categories in humans remains under research, with a sixth taste possibly including spicy or pungent.
According to the Federal Emergency Management Agency (FEMA), Waffle House is one of the top four corporations, along with Walmart, The Home Depot, and Lowe's, for disaster response. Waffle House has an extensive disaster management plan with on-site and portable generators, and positions food and ice ahead of severe weather events such as a hurricane. This helps mitigate the effects of a storm on the power grid and the supply chains. The company prepares "jump teams" of recovery staff and supplies, brought in from outside disaster-affected areas, so that local staff can focus on helping their own homes and families. The ability of a Waffle House to remain open after a severe storm, possibly with a limited menu, is used by FEMA as a measure of disaster recovery known as the Waffle House Index.
== Partnerships == Rose Pharma is currently funded by CAT Invest, Nordic Biotech, BML Healthcare and 123MultiNova Europe. In 2008, Rose Pharma signed an agreement with Eli Lilly and Company (Indianapolis, United States) to in-license a Lilly compound (formerly known as LY307161, now named ROSE-010), an analogue of the naturally occurring intestinal hormone GLP-1. The licensing agreement is a result of an ongoing research collaboration the two companies have participated in since 2004.
An increase in the expression of Group 2 mGluRs, which could arise from a chronic under stimulation of these receptors, has been associated with schizophrenia. An increase in levels of system Xc- has also been found in postmortem schizophrenia patients, indicating that there may have been a decrease in net function of these receptors as well, leading to greater expression. It has been observed that Schizophrenia patients have a decreased level of glutathione in their prefrontal cortex, further supporting the conclusion that system Xc- may not be functioning properly. Clinical trials have shown therapeutic potential for N-acetylcysteine in treating schizophrenia. Again, changes in EAATs due to disruptions in Glutamate homeostasis may also be involved. Recent study showed that mRNA expression levels of both SLC3A2 and SLC7A11 in WBCs of schizophrenia patients are lower than that of healthy individuals. The finding supports the hypo-glutamatergic neurotransmission hypothesis in schizophrenia.
Sources: en.wikipedia.org
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.
No. It is a shortened peptide fragment, not the full hormone. It does not contain the entire hGH sequence and is studied for different proposed effects.
Regulatory approvals for weight loss are not established in major jurisdictions. Some human trials reported modest changes, but the evidence is limited, and it remains a research compound.
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.